STRATA CRITICAL MEDICAL INC CLASS (SRTA)
Sector: Health Care
2026 Annual Meeting Analysis
STRATA CRITICAL MEDICAL INC CLASS · Meeting: May 28, 2026
Directors FOR
2
Directors AGAINST
0
Say on Pay
FOR
Auditor
FOR
Director Elections
Elect Class II Directors
Heyburn joined the board in August 2025, less than 24 months before the meeting, so he is exempt from the stock performance trigger under policy; his background as Co-CEO and CFO with deep knowledge of the company's strategy and capital structure is relevant, and no other disqualifying flags apply.
Lauck has served since March 2023 and the company's 3-year stock return of +47.4% outperformed its disclosed peer group median by +97.1 percentage points, well above the 65-percentage-point threshold required to trigger an against vote for a strong positive return; no other disqualifying flags apply, and his investment and finance background is relevant to the company's stage.
Both Class II director nominees — executive director Heyburn and independent director Lauck — pass all policy screens. Heyburn is exempt from the stock performance trigger due to his tenure of under 24 months. Lauck's tenure overlaps the performance period, but SRTA's 3-year return of +47.4% beat the company's own disclosed peer group median by +97.1 percentage points, far short of the 65-percentage-point underperformance threshold needed to trigger a vote against. No overboarding, attendance, independence, or qualification concerns are present for either nominee.
Say on Pay
✓ FORCEO
Melissa M. Tomkiel
Total Comp
$5,613,018
Prior Support
62.5%%
The prior year Say-on-Pay vote received only 62.5% support — below the 70% threshold that normally requires visible remediation or a No vote — but the company conducted extensive shareholder engagement (reaching stockholders representing approximately 50% of shares outstanding), made concrete changes to equity grant timing to address the accounting value disconnect cited by shareholders, and redesigned the 2026 long-term incentive plan to use a full three-year performance goal plus a relative total shareholder return modifier; these are meaningful, documented responses to shareholder concerns. The pay structure is predominantly performance-based (PSUs make up the large majority of equity compensation for the Co-CEOs and other named executive officers), with salary representing a modest portion of total compensation, and the short-term bonus payouts were tied to objective financial metrics that required real achievement above threshold. While the CEO's total compensation of approximately $5.6 million is substantial for a company with a $373 million market cap, the company underwent a fundamental business transformation in 2025 — selling its passenger segment and acquiring Keystone — placing heavy demands on leadership, and the compensation committee's responsiveness to prior shareholder feedback supports a For determination.
Auditor Ratification
✓ FORAuditor
Deloitte & Touche LLP
Tenure
N/A
Audit Fees
$1,333,663
Non-Audit Fees
$456,357
Non-audit fees (audit-related fees of $223,375 plus all other fees of $232,982, totaling $456,357) represent approximately 34% of audit fees ($1,333,663), which is well below the 50% threshold that would raise independence concerns; Deloitte is a Big 4 firm appropriate for a company of this size and complexity; auditor tenure is not disclosed so the tenure trigger cannot fire; and no material financial restatements are noted.
Overall Assessment
The 2026 Strata Critical Medical annual meeting presents three standard proposals — director elections, auditor ratification, and Say-on-Pay — all of which receive a For determination. The company's strong stock performance (3-year return of +47.4% versus a peer median of -49.7%) clears the director TSR trigger by a wide margin, the auditor fee structure is clean with non-audit fees well below the independence threshold, and while last year's Say-on-Pay received only 62.5% support, the company conducted robust shareholder engagement and made concrete, verifiable changes to its compensation program design in direct response to investor feedback.
Compensation Peer Group
15 companies disclosed in 2026 proxy filing